FLT3 anticorps

N° du produit ABIN2422676

Détail du produit anti-FLT3 anticorps

Antigène: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FLT3 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC)

Purification: Affinity purification

Immunogène: Recombinant protein of human FLT3

Isotype: IgG

Information d'application

Indications d'application: IHC 1:50-1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Agent conservateur: Sodium azide

Conseil sur la manipulation: Avoid freeze / thaw cycles.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Détails sur FLT3

Antigène: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Autre désignation: FLT3 (FLT3 Produits)

Synonymes: anticorps FLT3, anticorps B230315G04, anticorps CD135, anticorps Flk-2, anticorps Flk2, anticorps Flt-3, anticorps Ly72, anticorps wmfl, anticorps FLK-2, anticorps FLK2, anticorps STK1, anticorps fms related tyrosine kinase 3, anticorps FMS-like tyrosine kinase 3, anticorps fms-related tyrosine kinase 3, anticorps FLT3, anticorps Flt3

Sujet: This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.

Pathways: Signalisation RTK